Cure My Disease

Don't miss your cure!

 Log in / Sign up

Sleep hormone may boost fertility in women with low egg reserve

NCT ID NCT07318974

Symptom relief Sponsor: Benha University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether taking melatonin for 4 weeks before egg retrieval can improve egg quality and pregnancy rates in women with diminished ovarian reserve (low egg supply). The trial involves 64 women undergoing ICSI (a type of IVF). Half receive melatonin, half a placebo, and researchers compare pregnancy success rates.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

64 people

The number who actually took part.

Started

Sep 2025

Expected to finish

Mar 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirmed Diminished Ovarian Reserve (DOR) based on Bologna criteria (e.g., low AMH, low AFC). * Undergoing ICSI with frozen blastocyst transfer (FBT) protocol. * Willingness to comply with a 28-day pre-retrieval medication regimen. Exclusion Criteria: * Severe endometriosis or hydrosalpinx. * Uterine anomalies (e.g., large fibroids or uterine septums). * Chronic systemic diseases (e.g., uncontrolled diabetes or hypertension). * Partner with severe male factor infertility requiring TESE/PESA (to isolate the effect on oocyte quality). * Current use of other antioxidant supplements.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ICS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

primary ciliary dyskinesia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ICS

Contacts and locations

Locations

  • Benha university

    Banhā, El Qalyoubia, 13511, Egypt